This ASX All Ords biotech share is on a 16% tear today

What's getting investors excited about this biotech?

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Race Oncology Ltd (ASX: RAC) share price is catching the eye on Tuesday.

In morning trade, the ASX All Ords biotech share is up 16% to $1.05.

Why is this ASX All Ords biotech share on a tear?

Investors have been buying the oncology-focused biotechnology company's shares today following the release of a positive announcement.

This relates to interim clinical results from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine (Bis/Clo/Flu) in relapsed or refractory Acute Myeloid Leukaemia (R/R AML) patients.

According to the release, 6 of the 15 evaluable patients (40%) responded to Bis/Clo/Flu treatment (five complete responses, one partial response), with three of the clinical responders having active extramedullary disease (EMD).

Furthermore, the ASX All Ords biotech share revealed that five of the six treatment-responsive patients were able to be bridged to a stem cell transplant (SCT) within one to three months of treatment.

Of the five stem cell transplanted patients, three have since sadly died; one from graft-versus-host disease, one who relapsed within four months of transplant, and one of infection after two years. However, the two other patients remain disease-free and in complete remission.

The Director of Haematology at the Calvary Mater Newcastle and John Hunter Hospitals, Professor Dr Anoop Enjeti, commented:

This clinical trial of bisantrene in combination with intensive chemotherapy produced very encouraging results in younger AML patients with advanced relapsed, refractory and resistant acute myeloid leukaemia (AML). Many of these patients achieved a complete or a partial remission, enabling a significant proportion to go on to a bone marrow transplant. These impressive results provide proof of concept supporting further trials of bisantrene in combination with other AML treatments to improve outcomes for this leukaemia.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »